Member Info for KingHomerJ

The potential commercial value of personalized dosing software, like Physiomics plc's PREDICT-ONC, is significant due to the growing demand for precision medicine in oncology. Below are key areas where this technology can generate revenue and market value:

1. Market Demand & Growth Potential

• Global Oncology Market: Expected to reach $500+ billion by 2030, with a strong focus on personalized medicine.

• Chemotherapy Market: Personalized dosing can improve treatment outcomes and reduce side effects, making it highly valuable to healthcare providers.

• G-CSF Market: Drugs like Neulasta (pegfilgrastim) generate billions in revenue; optimizing their dosing can drive adoption.

2. Revenue Streams

a. Licensing to Hospitals & Clinics

• Subscription-based Software as a Medical Device (SaMD) model.

• Hospitals and oncology centers pay for annual licenses to integrate dosing software into treatment protocols.

b. Partnerships with Pharma & Biotech Companies

• Companies developing G-CSF drugs or chemotherapy agents can license the software for their clinical trials.

• Potential collaboration with big pharma players like Roche, Amgen, and Pfizer to enhance their oncology pipelines.

c. Integration with Electronic Health Records (EHR)

• Software can be embedded into EHR platforms like Epic or Cerner, streamlining use in clinical workflows.

• Health systems may pay for custom integrations or per-patient usage fees.

d. Regulatory Approval & Reimbursement

• Once approved by FDA, MHRA, EMA, software could be reimbursed by insurers, making it accessible to more hospitals.

• Health insurers might support adoption if it reduces chemotherapy-related complications and hospital readmissions.

3. Competitive Advantage

• AI-driven precision: If PREDICT-ONC demonstrates higher accuracy than standard dosing, it could dominate a niche market.

• Regulatory approval as a differentiator: Few predictive dosing tools are FDA-approved, giving first-mover advantage.

• Cost savings for hospitals: Optimized dosing reduces drug waste and treatment costs, making adoption attractive.

4. Long-Term Scalability

• Expansion into other cancer treatments (beyond G-CSF, into immunotherapy, targeted therapy).

• Potential to be used for other high-risk drug dosing, including antibiotics, anticoagulants, and biologics.

• Global expansion into emerging markets where precision medicine is gaining traction.

Potential Valuation Impact on Physiomics plc

If successfully commercialized, this technology will significantly boost Physiomics plc's valuation as they become a leader in the field of personalised medicine, attracting investors and potential acquisition offers from big pharma or med-tech companies.

Can I suggest this (think about it) a forum of

Random faceless bodies throwing mud at each other stops ,as this has zero benefit to any nor the company.

If fact it has a deferment impact.

Can I suggest we post relevant info - and stick to that……

Thanks

KHJ

LinkedIn

The FDA's guidance on dose optimisation for new cancer drugs, finalised in August 2024, marks a major shift in oncology drug development.

We've partnered with Weatherden to help break down the guidance and provide our thoughts on what this increased focus on dose optimisation means for the industry, from drug developers and trial sponsors to investors and regulators.

Read our full article to gain a deeper understanding of how this guidance can shape your drug development strategy 👇

Agreed they should have added to news today if that’s the case

Was announced on social media and linked in a few hours ago.

Mark only started working with the company in late November / early December…

Both parties have just announced this today…

“Our repeat and long-term clients have realised significant value gains since we became involved in their programmes, $25 Billion Dollars”

PYC just announced a partnership with weatherden

https://weatherden.co.uk/

The Beyond Blood Diagnostics and Physiomics tool, once approved, will provide significant value in personalized chemotherapy management, particularly in reducing the risks of chemotherapy-induced neutropenia (CIN).

Value of the Tool When Approved

1. Improved Patient Safety & Outcomes

Helps optimize G-CSF (Granulocyte Colony-Stimulating Factor) dosing, reducing severe neutropenia risks.

Enhances personalized chemotherapy dosing, minimizing side effects and improving treatment success.

2. At-Home Monitoring & Convenience

Patients can use Beyond Blood’s finger-prick blood test at home, reducing hospital visits.

Faster results allow timely interventions for neutropenia, preventing severe infections.

3. Cost Savings for Healthcare Systems (e.g., NHS)

Reduces unnecessary hospital admissions due to neutropenia-related complications.

Minimizes the need for frequent in-hospital blood tests, lowering operational burdens.

4. Enhanced Clinical Decision-Making

Physiomics’ AI-driven software assists oncologists in personalizing treatment plans based on patient-specific blood test results.

o Helps clinicians predict how a patient’s body will respond to chemotherapy.

Who Will Use This Tool?

1. Oncologists & Hematologists

To optimize chemotherapy dosing and prevent severe side effects.

To track patient blood cell counts remotely and adjust treatments accordingly.

2. Cancer Patients Undergoing Chemotherapy

Especially those receiving G-CSF therapy for neutropenia.

Enables self-monitoring at home, reducing hospital visits.

3. Healthcare Providers & NHS Hospitals

NHS and other healthcare institutions will use it to streamline cancer treatment.

Reduces hospital burden by minimizing unnecessary patient visits and emergency interventions.

4. Pharmaceutical & Biotech Companies

Can integrate this tool into clinical trials to enhance chemotherapy effectiveness.

Potential Market Impact

• If approved, the tool could become a standard part of cancer care, adopted widely by healthcare systems like the NHS, private hospitals, and oncology clinics worldwide.

• It may also lead to partnerships with pharmaceutical companies that develop chemotherapy drugs.

Avo - frankly you have zero idea about what you are talking about…..

You spoken to the company and its stakeholders….

No….. so frankly just shhhhhhhhhh

The potential commercial value of personalized dosing software, like Physiomics plc's PREDICT-ONC, is significant due to the growing demand for precision medicine in oncology. Below are key areas where this technology can generate revenue and market value:

1. Market Demand & Growth Potential

• Global Oncology Market: Expected to reach $500+ billion by 2030, with a strong focus on personalized medicine.

• Chemotherapy Market: Personalized dosing can improve treatment outcomes and reduce side effects, making it highly valuable to healthcare providers.

• G-CSF Market: Drugs like Neulasta (pegfilgrastim) generate billions in revenue; optimizing their dosing can drive adoption.

2. Revenue Streams

a. Licensing to Hospitals & Clinics

• Subscription-based Software as a Medical Device (SaMD) model.

• Hospitals and oncology centers pay for annual licenses to integrate dosing software into treatment protocols.

b. Partnerships with Pharma & Biotech Companies

• Companies developing G-CSF drugs or chemotherapy agents can license the software for their clinical trials.

• Potential collaboration with big pharma players like Roche, Amgen, and Pfizer to enhance their oncology pipelines.

c. Integration with Electronic Health Records (EHR)

• Software can be embedded into EHR platforms like Epic or Cerner, streamlining use in clinical workflows.

• Health systems may pay for custom integrations or per-patient usage fees.

d. Regulatory Approval & Reimbursement

• Once approved by FDA, MHRA, EMA, software could be reimbursed by insurers, making it accessible to more hospitals.

• Health insurers might support adoption if it reduces chemotherapy-related complications and hospital readmissions.

3. Competitive Advantage

• AI-driven precision: If PREDICT-ONC demonstrates higher accuracy than standard dosing, it could dominate a niche market.

• Regulatory approval as a differentiator: Few predictive dosing tools are FDA-approved, giving first-mover advantage.

• Cost savings for hospitals: Optimized dosing reduces drug waste and treatment costs, making adoption attractive.

4. Long-Term Scalability

• Expansion into other cancer treatments (beyond G-CSF, into immunotherapy, targeted therapy).

• Potential to be used for other high-risk drug dosing, including antibiotics, anticoagulants, and biologics.

• Global expansion into emerging markets where precision medicine is gaining traction.

Potential Valuation Impact on Physiomics plc

If successfully commercialized, this technology will significantly boost Physiomics plc's valuation as they become a leader in the field of personalised medicine, attracting investors and potential acquisition offers from big pharma or med-tech companies.

After the PREDICT-ONC trial is completed, several key steps follow to assess its success and determine the next steps for Physiomics plc's personalized dosing software. Here's what typically happens:

1. Data Analysis & Validation

• The collected patient data is analyzed to determine how well the predictive software performed in estimating optimal G-CSF dosing.

• Researchers will compare predicted vs. actual patient responses to assess the accuracy and effectiveness of the model.

• Statistical analysis will be conducted to identify trends and refine the algorithm.

2. Regulatory Submissions & Approvals

• If the results are promising, Physiomics may submit the findings to regulatory bodies like:

o MHRA (UK Medicines and Healthcare products Regulatory Agency)

o FDA (U.S. Food and Drug Administration)

o EMA (European Medicines Agency)

• These agencies will review the data to assess the software's safety and efficacy for clinical use.

3. Further Clinical Trials or Real-World Testing

• If necessary, larger trials may be conducted to validate the software across different cancer types or broader patient populations.

• The software might be integrated into real-world oncology settings for further refinement.

4. Commercialization & Partnerships

• If regulatory approval is obtained, Physiomics may commercialize the software for use in hospitals and oncology clinics.

• Potential collaborations with pharmaceutical companies, biotech firms, or healthcare providers to expand usage.

5. Integration into Clinical Practice

• The software could become a standard tool for oncologists to personalize chemotherapy dosing.

• This would help reduce side effects and improve treatment efficacy for cancer patients.

The PREDICT-ONC project by Physiomics plc is an observational clinical trial designed to enhance their personalized dosing software for chemotherapy patients. The primary focus is on G-CSF (Granulocyte Colony-Stimulating Factor), a drug used to manage neutropenia, a side effect of chemotherapy that weakens the immune system.

Process of PREDICT-ONC

1. Regulatory & Ethical Approvals

o The project secured approvals in the UK to commence patient recruitment.

o Supported by a £137,376 grant from Innovate UK and the Office for Life Sciences.

2. Patient Recruitment

o Conducted at Blackpool Teaching Hospitals NHS Foundation Trust.

o Involves breast cancer patients receiving standard G-CSF treatment.

o Expected to begin in early 2025, with completion targeted by late 2025.

3. Data Collection & Monitoring

o Patients' responses to G-CSF treatment are monitored.

o Key factors like white blood cell counts and immune response are recorded.

4. Software Optimization

o Collected data is fed into Physiomics' predictive software.

o The AI-driven model refines dosing recommendations based on patient-specific responses.

o Goal: More accurate, personalized chemotherapy dosing to minimize side effects.

5. Analysis & Future Applications

o Trial results will validate the software’s accuracy.

o If successful, the tool could be integrated into clinical practice, improving cancer treatment outcomes.

Lots of news to come....

The 16 Million MC it was 2 years ago is the first step....(Thats 8p per share) that's still cheap as we are way way down the line

* pipeline & Highest revenue to date - more contracts due and in discussions as per company update

* New ADC's contracts & development into VT Tech

* Dosemerx Update - incoming !

* NHS Trial - incoming

*Precision prostate cancer dosing tool (Grant funded) Incoming

* Beyond Blood Diagnostics update incoming

* The AI Virtual Tumour platform getting endorsed by Major multi billion £ pharmas.... (as proven by the peer review papers) One more peer review to land

* FDA stated there is now a requirement for modelling within drug development......

* New Biostats arm of the business launched in November due update & Contracts (which will be the same / if not more revenue that the VT - as stated in the last investors presentation.

*The end of the PRECISE-ONC trial in October with the NHS and Beyond blood if positive will take the doing tool straight to FDA approval…for medical use…..at this point the company will more than likely get taken out as that tool alone can / should save multi millions and is a pathway to market….globally - NHS etc

I have spoken to the company and they will be giving updates.

Let’s not forget…..let’s just base the conversation on this bb on facts…..

Also let’s not throw mud at each other and focus on research and facts.

Lots of news to come....

The 16 Million MC it was 2 years ago is the first step....(Thats 8p per share) that's still cheap as we are way way down the line

* pipeline & Highest revenue to date - fact !

* New ADC's contracts & development into VT Tech

* Dosemerx Update - incoming !

* NHS Trial - incoming

*Precision prostate cancer dosing tool (Grant funded)

* Beyond Blood Diagnostics update incoming

* The AI Virtual Tumour platform getting endorsed by Major multi billion £ pharmas.... (as proven by the peer review papers)

* FDA stated there is now a requirement for modelling within drug development...... (fact)

* New Biostats arm of the business launched in November due update & Contracts (which will be the same / if not more revenue that the VT - as stated in the last investors presentation. (Incoming & fact)

*New TR1 Holder (fact)

Also if the company get a “new contract” then surely think about it……prior to interims….. company is AHEAD of EXPECTATIONS

I’ll leave anyone to research this and prove me wrong…..wont happen……

I’ve bought more this morning on the dip…

Firstly the 2 and forth sling mud is very unproductive…and a waste of energy all everyone behalf… the people involved and the people that have to read it.

If anyone has any questions I would suggest emailing the company.

I have and I am very pleased with the response. About the direction, current situation, the news flow we are still awaiting as well as numerous strategic initiatives.

I’m happy to hold onto my millions of shares

Trout i will need to double check but I'm sure the investors presentation mentioned the Pipeline being 2mil (granted this means contracts will need to be signed and confirmed)

1.40 is a good start to the rerate….still a long long way to go tbf

We all know at 2.5m MC it’s seriously undervalued especially when some peers generate zero revenue and huge losses but have MC’s in the £10’s millions